Zelda Therapeutics Expands its Research Programme Internationally with Clinical Trials Commencing in Chile • Zelda Therapeutics will launch its clinical trial programme in Chile in the second half of this year • Clinical trials to target insomnia and eczema • Leverages relationship with ASX-listed AusCann which through its joint venture in Chile, DayaCann, is the only licensed grower of medical cannabis in Chile • Zelda intends to register products for sale in Chile should trials be successful providing a pathway to maiden revenues • Chile has a robust regulatory environmen
